TY - JOUR
T1 - Practical effectiveness of re-irradiation with or without surgery for locoregional recurrence of rectal cancer
T2 - A meta-analysis and systematic review
AU - Lee, Jeongshim
AU - Kim, Chul Yong
AU - Koom, Woong Sub
AU - Rim, Chai Hong
N1 - Funding Information:
This work was supported by the National Research Fund of Korea [grant number NRF-2019M2D2A1A01031560 ].
Funding Information:
This work was supported by the National Research Fund of Korea [grant number NRF-2019M2D2A1A01031560]. The authors have declared no conflicts of interest.
PY - 2019/11
Y1 - 2019/11
N2 - Background and purpose: Re-irradiation might yield local control (LC) or palliation for locoregionally recurrent rectal cancer (LRRC), but iatrogenic complications are a possible hindrance. We aimed to evaluate the efficacy of re-irradiation to determine optimal treatment of LRRC. Methods: We performed a systematic review of PubMed, MEDLINE, Cochrane Library, and Embase. Results: A total of 17 studies involving 744 patients with LRRC were included; median OS ranging from 10 to 45 months (median: 24.5 months). Pooled 1-, 2-, and 3-year OS rates for all patients were 76.1%, 49.1%, and 38.3%, respectively. For patients who underwent re-irradiation and surgery (OP group), these pooled rates were 85.9%, 71.8%, and 51.7%, respectively. For patients who underwent re-irradiation but not surgery (non-OP group), pooled 1-, 2-, and 3-year OS rates were 63.5%, 34.2%, and 23.8%, respectively. The OS difference between both groups was significant for all 3 years (P < 0.05). Pooled 1-, 2-, and 3-year LC rates for the OP group were 84.4%, 63.8%, and 46.9%, and for the non-OP group were 72.0%, 54.8%, and 44.6%, respectively, without significant differences. Pooled grade ≥3 acute and late complication rates were 11.7% and 25.5% in the OP and non-OP groups, respectively. Patients who underwent surgery had a higher risk of grade ≥3 late complications (odds ratio: 6.39). Pooled symptomatic palliation rate was 75.2%. Conclusions: Re-irradiation with or without surgery for LRRC showed oncologic and palliative efficacy. Salvage treatment including re-irradiation and surgery showed higher survival, but the late complication was significantly increased with concomitant surgery.
AB - Background and purpose: Re-irradiation might yield local control (LC) or palliation for locoregionally recurrent rectal cancer (LRRC), but iatrogenic complications are a possible hindrance. We aimed to evaluate the efficacy of re-irradiation to determine optimal treatment of LRRC. Methods: We performed a systematic review of PubMed, MEDLINE, Cochrane Library, and Embase. Results: A total of 17 studies involving 744 patients with LRRC were included; median OS ranging from 10 to 45 months (median: 24.5 months). Pooled 1-, 2-, and 3-year OS rates for all patients were 76.1%, 49.1%, and 38.3%, respectively. For patients who underwent re-irradiation and surgery (OP group), these pooled rates were 85.9%, 71.8%, and 51.7%, respectively. For patients who underwent re-irradiation but not surgery (non-OP group), pooled 1-, 2-, and 3-year OS rates were 63.5%, 34.2%, and 23.8%, respectively. The OS difference between both groups was significant for all 3 years (P < 0.05). Pooled 1-, 2-, and 3-year LC rates for the OP group were 84.4%, 63.8%, and 46.9%, and for the non-OP group were 72.0%, 54.8%, and 44.6%, respectively, without significant differences. Pooled grade ≥3 acute and late complication rates were 11.7% and 25.5% in the OP and non-OP groups, respectively. Patients who underwent surgery had a higher risk of grade ≥3 late complications (odds ratio: 6.39). Pooled symptomatic palliation rate was 75.2%. Conclusions: Re-irradiation with or without surgery for LRRC showed oncologic and palliative efficacy. Salvage treatment including re-irradiation and surgery showed higher survival, but the late complication was significantly increased with concomitant surgery.
KW - Complication
KW - Re-irradiation
KW - Rectal cancer
KW - Recurrence
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=85066478593&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066478593&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2019.05.021
DO - 10.1016/j.radonc.2019.05.021
M3 - Review article
C2 - 31176204
AN - SCOPUS:85066478593
SN - 0167-8140
VL - 140
SP - 10
EP - 19
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
ER -